1902 related articles for article (PubMed ID: 24471303)
1. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.
Barrie A; Regueiro M
Inflamm Bowel Dis; 2007 Nov; 13(11):1424-9. PubMed ID: 17567879
[TBL] [Abstract][Full Text] [Related]
4. The effect of infliximab on extraintestinal manifestations of Crohn's disease.
Kaufman I; Caspi D; Yeshurun D; Dotan I; Yaron M; Elkayam O
Rheumatol Int; 2005 Aug; 25(6):406-10. PubMed ID: 15309501
[TBL] [Abstract][Full Text] [Related]
5. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease.
Siemanowski B; Regueiro M
Curr Treat Options Gastroenterol; 2007 Jun; 10(3):178-84. PubMed ID: 17547856
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.
Bernstein CN; Blanchard JF; Rawsthorne P; Yu N
Am J Gastroenterol; 2001 Apr; 96(4):1116-22. PubMed ID: 11316157
[TBL] [Abstract][Full Text] [Related]
8. Biologics for extraintestinal manifestations of IBD.
Vavricka SR; Scharl M; Gubler M; Rogler G
Curr Drug Targets; 2014; 15(11):1064-73. PubMed ID: 25198785
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
[TBL] [Abstract][Full Text] [Related]
10. Extraintestinal manifestations in inflammatory bowel disease: Prevalence and predictors in Indian patients.
Bandyopadhyay D; Bandyopadhyay S; Ghosh P; De A; Bhattacharya A; Dhali GK; Das K
Indian J Gastroenterol; 2015 Sep; 34(5):387-94. PubMed ID: 26614005
[TBL] [Abstract][Full Text] [Related]
11. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease.
Reguiaï Z; Grange F
Am J Clin Dermatol; 2007; 8(2):67-77. PubMed ID: 17428111
[TBL] [Abstract][Full Text] [Related]
12. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy.
Agarwal A; Andrews JM
Aliment Pharmacol Ther; 2013 Sep; 38(6):563-72. PubMed ID: 23914999
[TBL] [Abstract][Full Text] [Related]
13. Skin Manifestations of Inflammatory Bowel Disease.
Greuter T; Navarini A; Vavricka SR
Clin Rev Allergy Immunol; 2017 Dec; 53(3):413-427. PubMed ID: 28643285
[TBL] [Abstract][Full Text] [Related]
14. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
[TBL] [Abstract][Full Text] [Related]
15. Extraintestinal Manifestations of Inflammatory Bowel Disease.
Vavricka SR; Schoepfer A; Scharl M; Lakatos PL; Navarini A; Rogler G
Inflamm Bowel Dis; 2015 Aug; 21(8):1982-92. PubMed ID: 26154136
[TBL] [Abstract][Full Text] [Related]
16. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.
Vavricka SR; Rogler G; Gantenbein C; Spoerri M; Prinz Vavricka M; Navarini AA; French LE; Safroneeva E; Fournier N; Straumann A; Froehlich F; Fried M; Michetti P; Seibold F; Lakatos PL; Peyrin-Biroulet L; Schoepfer AM
Inflamm Bowel Dis; 2015 Aug; 21(8):1794-800. PubMed ID: 26020601
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease.
Barreiro-de-Acosta M; Lorenzo A; Domínguez-Muñoz JE
Rev Esp Enferm Dig; 2012 Sep; 104(9):468-72. PubMed ID: 23130854
[TBL] [Abstract][Full Text] [Related]
18. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.
Rogler G; Singh A; Kavanaugh A; Rubin DT
Gastroenterology; 2021 Oct; 161(4):1118-1132. PubMed ID: 34358489
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.
Argüelles-Arias F; Castro-Laria L; Lobatón T; Aguas-Peris M; Rojas-Feria M; Barreiro-de Acosta M; Soto-Escribano P; Calvo-Moya M; Ginard-Vicens D; Chaparro-Sánchez M; Hernández-Durán M; Castro-Senosiain B; Fernández-Villaverde A; García-Sánchez V; Domínguez-Muñoz E; Caunedo-Álvarez A; Herrerías-Gutiérrez JM
Dig Dis Sci; 2013 Oct; 58(10):2949-54. PubMed ID: 23828140
[TBL] [Abstract][Full Text] [Related]
20. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
